Abstract 749P
Background
In the RUBY (NCT03981796) trial, dostarlimab (D)+carboplatin/paclitaxel (CP) demonstrated significant PFS improvement compared to placebo (PBO)+CP in pts with pA/rEC. PROs are reported here for the dMMR/MSI-H population.
Methods
Pts with pA/rEC were randomized 1:1 to D+CP or PBO+CP Q3W (6 cycles) followed by D or PBO monotherapy Q6W ≤3 years or disease progression. EORTC QLQ-C30 and EORTC QLQ-EN24 were secondary endpoints. PROs were administered at baseline (BL), day 1 of each cycle (C), end of treatment (EOT), and all follow-ups. Change (chg) from BL to EOT was calculated for assessed scales. Mixed models for repeated measures were used to generate least-squares means (LSM), adjusting for within-pt correlations across time points within a pt and controlling for BL values. Improvement is indicated by higher scores for QoL and functional scales and lower scores for symptom scales.
Results
Of 494 pts enrolled, 118 were dMMR/MSI-H. Mean BL scores and mean chg from BL to EOT for global QoL, functional scales, and select symptom are shown in the table. Mean chg from BL to EOT showed improvement in global QoL, emotional and social function, pain, and back/pelvis pain for D+CP. Only back/pelvis pain showed improvement for PBO+CP. Significant differences (LSM [standard error]) between arms were reported for chg from BL to EOT for QoL (14.7 [5.45]; P=0.008), role (12.7 [5.92]; P=0.032), emotional (14.3 [4.92]; P=0.004) and social function (13.5 [5.43]; P=0.014), and fatigue (-13.3 [5.84]; P=0.025).
Conclusions
Pts receiving D+CP demonstrated improvements in several QoL domains relative to BL at EOT, with significant improvements over PBO+CP, in global QoL, role, emotional, and social function, and fatigue. Dostarlimab+CP significantly improved PFS while maintaining QoL, further supporting its use as a standard of care in pts with dMMR/MSI-H pA/rEC. Table: 749P
D+CP | PBO+CP | |||
BL Mean (SD) | BL to EOT Mean chg (SD) | BL Mean (SD) | BL to EOT Mean chg (SD) | |
EORTC QLQ-C30 | ||||
Global QoL | 66.7 (25.9) | 3.0 (19.4) | 67.3 (23.9) | -11.1 (29.1) |
Physical F | 74.9 (21.8) | -5.0 (17.1) | 69.1 (23.3) | -6.1 (26.9) |
Role F | 66.6 (32.2) | 0.9 (29.7) | 72.9 (32.2) | -7.8 (36.6) |
Emotional F | 75.9 (18.1) | 9.2 (17.5) | 75.9 (20.1) | -6.7 (30.4) |
Cognitive F | 86.3 (20.7) | -1.5 (17.8) | 88.0 (19.3) | -9.3 (31.5) |
Social F | 74.5 (30.3) | 6.1 (34.7) | 80.2 (27.2) | -12.0 (33.8) |
Pain a | 32.3 (27.3) | -3.0 (29.7) | 32.3 (32.1) | 8.2 (32.8) |
Fatigue a | 33.9 (25.2) | -5.1 (26.9) | 35.1 (27.7) | 7.2 (36.0) |
EORTC QLQ-EN24 | ||||
Back and pelvis pain a | 35.3 (31.0) | -10.8 (24.0) | 36.5 (32.7) | -3.1 (38.3) |
aLower scores indicate reduced symptom severity F, function
Clinical trial identification
NCT01847274.
Editorial acknowledgement
Writing and editorial support, funded and coordinated by GSK, was provided by Shannon Morgan-Pelosi, PhD, and Mary C. Wiggin, of Ashfield MedComms, an Inizio company.
Legal entity responsible for the study
GSK.
Funding
GSK.
Disclosure
G. Valabrega: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, AstraZeneca, Clovis Oncology, GSK, PharmaMar, Roche, Tesaro. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Tesaro, Merck, Eisai, Clovis Oncology, AstraZeneca. S. Hietanen: Financial Interests, Personal, Other: GSK; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Orion Pharma; Financial Interests, Personal, Expert Testimony: AstraZeneca, GSK. E.M. Miller: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK, Tempus; Financial Interests, Personal, Other: OncLive, Opinions in Gyn Malignancies. Z. Novák: Financial Interests, Personal, Speaker, Consultant, Advisor: Sofmedica, AstraZeneca, MSD, Preglem; Financial Interests, Personal, Advisory Board: Richter Gedeon; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Stocks/Shares: Richter Gedeon. R. Holloway: Financial Interests, Personal, Other: GSK, AstraZeneca, Clovis, Eisai, Merck; Financial Interests, Personal, Stocks or ownership: Genelux. D. Denschlag: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK/Tesaro, Roche, Eisai Germany, MSD Oncology, MSD, Intuitive Surgical, KLS Martin; Financial Interests, Personal, Other, travel expenses: AstraZeneca; Financial Interests, Personal, Other: Roche. T. Myers: Financial Interests, Personal, Other: Immunogen. A.M. Thijs: Financial Interests, Institutional, Funding: Alkermes, AstraZeneca, Clovis, Esperas, IMV, ImmunoGen Inc., Karyopharm, Merck Sharp & Dohme, Mersana, Novocure GmbH, OncoQuest Pharmaceuticals, Pfizer, Roche, and Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck; Financial Interests, Personal, Other: Alkermes, AstraZeneca, Eisai, Eisai-Merck, and GSK. L. Gilbert: Financial Interests, Institutional, Funding: Alkermes, AstraZeneca, Clovis, Esperas, IMV, ImmunoGen Inc., Karyopharm, Merck Sharp & Dohme, Mersana, Novocure GmbH, OncoQuest Pharmaceuticals, Pfizer, Roche, Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, AstraZeneca, Eisai, Eisai-Merck, GSK; Financial Interests, Personal, Other: Alkermes. L. Copeland: Financial Interests, Institutional, Funding: AbbVie, Advaxis, Agenus, Ajinomoto, Arcus Biosciences Inc., Array BioPharm, AstraZeneca, BeiGene USA Inc., BMS, Cerulean Pharma, Clovis Oncology, Deciphera Pharma, Eisai, EMD Serano, Ergomed Clinical Research, Exelixis, Genetech/Roache, Genmab, GSK, Hoffmann-LaRoche, Immunogen, Leap Therapeutics, Ludwig Institute of Pharmaceuticals, Merck, Mersana Therapeutics, Novocure, OncoQuest, PharmaMar USA, Pfizer, PRA International, Precision Therapeutics, Regeneron, Sanofi, Seattle Genetics, Serono, Stemcentrix, Sumitomo Dainippon Pharma Oncology, Sutro Biopharm, Tesaro (GSK), TRACON Pharm, Verastem; Financial Interests, Personal, Advisory Board: A28 Therapeutics, Celsion Corporation, Corcept Therapeutics, Elevar Therapeutics, GSK, Immunogen, Inx Med, Luzsana Biotechnology, Myriad Genetics, OncoNova, Rubius Therapeutics, Sorrento Therapeutics, Toray Industries, Inc., VBL Therapeutics; Financial Interests, Personal, Member: DMCC for Corcept Therapeutics. R. Gogoi: Financial Interests, Personal, Advisory Board: Pionyr Pharmaceuticals; Financial Interests, Personal, Other: Bausch + Lomb. N. Cloven: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, Toray Pharmaceuticals. O. Meyers, J. Garside: Financial Interests, Personal, Full or part-time Employment: GSK. M.R. Mirza: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Karyopharm, Merck, Roche, Zailab; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK; Financial Interests, Personal, Member of Board of Directors: Karyopharm; Financial Interests, Personal, Stocks/Shares: Karyopharm; Financial Interests, Institutional, Research Grant: GSK, AstraZeneca, ultimovacs, Apexigen; Financial Interests, Institutional, Trial Chair: Deciphera; Non-Financial Interests, Advisory Role: Ultimovacs, Apexigen. D. Black: Financial Interests, Institutional, Funding: GSK; Financial Interests, Personal, Membership or affiliation: GOG Partners Investigational Council; Financial Interests, Personal, Ownership Interest: Trials365, LLC. All other authors have declared no conflicts of interest.
Resources from the same session
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11